UPR/MDACC: Partnership for Excellence in Cancer Research (2 of 2)

整体 项目概要/摘要 这次竞争性的癌症研究卓越合作伙伴关系（合作伙伴关系）的更新， 波多黎各大学（UPR）和德克萨斯大学MD安德森癌症中心（MDACC）将：1） 巩固、加强和扩大普遍定期审议与MDACC之间的关系; 2）利用 在UPR综合癌症中心过渡中经验丰富的综合伙伴关系的优势 （UPRCCC）朝着一个长期的总体目标：承认UPRCCC作为NCI指定的癌症中心。到 为了解决波多黎各和得克萨斯州一些最严重的癌症健康差距，该伙伴关系将 建立一个促进职业发展和转化科学的创新驱动的创新计划 （影响）。该应用程序代表了一种合作关系，在这种合作关系中，两个机构都从共享不同的 在实施综合团队科学、外联、教育和职业方面互利的专业知识 发展举措。为了促进普遍定期审议理事会过渡到国家信息理事会，普遍定期审议项目负责人领导了 在MDACC PI的支持下制定具体目标。更新的具体目标是：1） 发展多学科研究组合，重点关注由感染驱动的健康差异 恶性肿瘤; 2）增加在实验室和人口中从事职业的西班牙裔学生的数量- 基于癌症研究，以产生临床医生，科学家和医生科学家的临界质量， 专门从事癌症研究，重点是代表性不足的少数民族的癌症健康差异， 3）加强所有利益攸关方之间的可持续合作， 促进旨在降低癌症发病率的关键社区外展、教育和干预措施， 强调在德克萨斯州PR的西班牙裔/拉丁裔人群中接种预防恶性肿瘤相关感染的疫苗， 4）利用与国家癌症研究所指定的癌症中心的战略合作， 普遍定期审议和联合国癌症理事会的癌症研究能力;以及5）提供专业支持和发展 通过a）行政管理; B）规划和评估;以及c）共享资源核心， 培育和优化伙伴关系的研究、教育和外联议程，以支持长期的 NCI-designated癌症中心的目标。这一推动伙伴关系的应用程序的关键要素包括： 1)多学科合作研究项目侧重于IMPACT， 转化研究连续体; 2）以癌症为重点的综合培训和职业发展核心; 3)双MD/MPH学位的发展，以解决特定的癌症不成比例地影响 西班牙裔人口; 4）努力建立，教育和倡导广泛的HPV疫苗接种计划; 以及5）构建基础设施的DATAOmics Core。这一举措将加强整体癌症研究 企业在感染驱动的恶性肿瘤在PR和TX，并将支持实施 UPRCCC的路线图，以提交癌症中心支持补助金（P30）的NCI指定。

OVERALL PROJECT SUMMARY / ABSTRACT This competitive renewal of the Partnership for Excellence in Cancer Research (Partnership) between the University of Puerto Rico (UPR) and the University of Texas MD Anderson Cancer Center (MDACC) will: 1) solidify, strengthen, and expand the relationship between UPR and MDACC; and 2) leverage the breadth and strengths of an experienced and integrated Partnership in transition of the UPR Comprehensive Cancer Center (UPRCCC) towards a long-term overall goal: recognition of UPRCCC as an NCI-designated cancer center. To address some of the most profound cancer health disparities in Puerto Rico and Texas, the Partnership will establish an Infection-Driven Malignancies Program for Advancing Careers and Translational Sciences (IMPACT). This application represents a partnership in which both institutions profit from sharing distinct expertise to mutually benefit in implementation of integrated team science, outreach, education and career development initiatives. To facilitate UPRCCC’s transition towards NCI-designation, the UPR PIs led the development of the specific aims with support of the MDACC PIs. The Specific Aims for the renewal are: 1) Develop a multidisciplinary research portfolio focused on health disparities derived from infection-driven malignancies; 2) Increase the number of Hispanic students pursuing careers in laboratory and population- based cancer research to produce a critical mass of clinicians, scientists, and physician-scientists, who specialize in cancer research, with emphasis on cancer health disparities in underrepresented minorities and underserved communities; 3) Strengthen sustainable collaborations among all the stakeholders to develop and promote key community outreach, education, and interventions aimed at reducing cancer rates and emphasizing vaccinations against malignancy linked infections, among Hispanic/Latino populations in PR, TX, and elsewhere; 4) Leverage strategic collaborations with NCI-designated cancer centers to augment the cancer research capacity of the UPR and the UPRCCC; and 5) Provide professional support and development tools through the a) Administration; b) Planning and Evaluation; and c) Shared Resources Cores designed to nurture and optimize the Partnership’s research, education, and outreach agendas in support of the long-term goal of an NCI-designated Cancer Center. Key elements of this application to advance the Partnership include: 1) Multidisciplinary collaborative research projects focused on IMPACT that represent stages of the translational research continuum; 2) A comprehensive cancer-focused training and career development core; 3) The development of a dual MD/MPH degree to address specific cancers disproportionately affecting Hispanic populations; 4) Outreach efforts to build, educate, and advocate for broad HPV vaccination programs; and 5) a DATAOmics Core that builds infrastructure. This initiative will strengthen the overall cancer research enterprise in infection-driven malignancies in both PR and TX, and will support the implementation of UPRCCC’s roadmap to submission of a Cancer Center Support Grant (P30) for NCI designation.